Sanofi Sees Immunology Momentum Heading Toward Cures
Sanofi is looking to develop new mechanisms of action and multi-targeted approaches in immunology and inflammation, with a vision of targeting disease causes rather than symptomatic improvement.
You may also be interested in...
The partners are looking to create a compelling value proposition for the interleukin-6 inhibitor, approved by FDA to treat moderate to severe RA, by pricing it below the market-leading anti-TNFs.
The FDA approved the IL-4/IL-13 inhibitor March 28 in a win for Sanofi and Regeneron. The companies set the biologic's price at $37,000 per year, which is lower than many biologics on the market for psoriasis.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.